Telix Pharmaceuticals Reports FY Earnings Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy TLX?
Source: seekingalpha
- Earnings Miss: Telix Pharmaceuticals reported a FY GAAP EPS of -$2.11, missing expectations by $2.14, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Growth Below Expectations: The company achieved revenue of $803.8 million, a 55.6% year-over-year increase, yet fell short of expectations by $22.79 million, suggesting that despite strong sales growth, market demand did not fully meet projections, potentially impacting future investment decisions.
- Market Reaction Analysis: Given the earnings miss, Telix Pharmaceuticals' stock price may face downward pressure, prompting investors to closely monitor the company's strategic adjustments and market performance to assess its potential for regaining profitability.
- Industry Context Impact: In the context of increasing competition within the healthcare sector, Telix Pharmaceuticals' financial performance highlights challenges in R&D and market promotion, indicating a need to reassess its business strategy to maintain competitive positioning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Telix Hosts Webinar on Innovations in PSMA-PET/CT Imaging for Prostate Cancer
- Webinar Announcement: Telix Pharmaceuticals is set to host a webinar on March 4, 2026, inviting medical experts to discuss innovations in PSMA-PET/CT imaging for prostate cancer, which is expected to attract a wide range of healthcare professionals and enhance the company's influence in the oncology imaging sector.
- Strong Expert Lineup: The speakers include Dr. Rodney Hicks from the University of Melbourne and Dr. Paul Yonover from UroPartners, showcasing Telix's extensive connections and collaborations in the medical community, potentially boosting investor confidence in the company's future developments.
- Global Business Presence: With its headquarters in Melbourne, Australia, Telix has expanded its international operations to the U.S., U.K., Brazil, Canada, Europe, and Japan, indicating its commitment to addressing global market needs in oncology and rare diseases, thereby enhancing its competitive edge.
- Commitment to Innovation: Telix focuses on developing therapeutic and diagnostic radiopharmaceuticals aimed at addressing significant unmet medical needs in oncology, which is expected to drive future growth through continuous technological advancements and enhance shareholder value.
See More
Telix Pharmaceuticals Hosts Webinar on Prostate Imaging Innovations
- Webinar Announcement: Telix Pharmaceuticals is set to host a webinar on March 4, 2026, featuring key opinion leaders discussing innovations in PSMA-PET/CT imaging for prostate cancer, which is expected to attract attention from investors and healthcare professionals, thereby enhancing the company's influence in the medical imaging field.
- Strong Expert Lineup: The speakers include Dr. Rodney Hicks from the University of Melbourne and Dr. Paul Yonover from UroPartners, showcasing Telix's extensive connections and influence in the medical community, potentially boosting investor confidence in the company's future developments.
- Global Business Presence: Telix operates internationally across the U.S., U.K., Brazil, Canada, Europe, and Japan, focusing on the development of radiopharmaceuticals for oncology and rare diseases, highlighting its strategic importance and market potential in the biopharmaceutical sector.
- Strengthening Investor Relations: By hosting this webinar, Telix aims to enhance interaction with investors and demonstrate its innovative capabilities in prostate cancer imaging technology, intending to improve its brand image and attract more investor interest in its future product development and market performance.
See More
Telix Collaborates with University Hospital Essen on Prostate Cancer Research
- Research Collaboration Initiated: Telix Pharmaceuticals has partnered with University Hospital Essen to launch the PROMISE-PET registry study, aimed at evaluating the prognostic value of PSMA-PET imaging through artificial intelligence, thereby standardizing prostate cancer management.
- Data Collection Scale: Since 2018, the registry has collected data from over 15,000 patients and standardized PET readings across more than 50 institutions globally, demonstrating the potential of PSMA-PET as a novel prognostic biomarker for prostate cancer.
- AI Model Development: The new collaboration will leverage Telix's automated machine learning platform to develop survival prediction models based on 68Ga-PSMA-11-PET imaging data, aiming to enhance the accuracy and effectiveness of clinical decision-making.
- Significant Clinical Impact: PSMA-PET imaging is recognized as a significant advancement in prostate cancer management, offering greater accuracy than conventional imaging, and is expected to influence clinical guidelines and decision-making through improved risk stratification.
See More
Telix Pharmaceuticals: Unlocking Potential in Cancer Diagnostics Market
- Market Growth Potential: A study by Precedence Research forecasts that the cancer diagnostics market will grow at a compound annual growth rate of 8.33% from 2026 to 2035, reaching $378.4 billion, highlighting rapid development and investment opportunities in this sector.
- Rapid Revenue Growth: Telix Pharmaceuticals reported revenue of $804 million in 2025, a 56% increase, with projections for 2026 revenue between $950 million and $970 million, primarily driven by sales progress of Illuccix and Gozellix, indicating increasing market acceptance of its products.
- Diversified Product Portfolio: Telix has two key drugs, TLX591 and TLX250, in phase 3 trials targeting prostate and kidney cancers, respectively, while also pursuing approvals for Zircaix and Pixclara, showcasing its extensive positioning in cancer treatment.
- Building Competitive Advantage: By acquiring RLS Pharmacies for $250 million, Telix established a radiopharmacy network with 31 locations, ensuring distribution capabilities for its radiopharmaceuticals, thereby gaining a significant edge in the market and enhancing its competitive position.
See More
Telix Pharmaceuticals Reports 56% Revenue Growth in 2025
- Significant Revenue Growth: Telix Pharmaceuticals reported a revenue of $804 million in 2025, marking a 56% increase, indicating strong market demand for cancer treatments and likely continued investor interest in the company.
- Optimistic Sales Outlook: Management forecasts 2026 revenue between $950 million and $970 million, a 19% increase at the midpoint, primarily driven by sales progress of Illuccix and Gozellix, reflecting growing market acceptance of its products.
- R&D Pipeline Expansion: Telix is advancing four late-stage and six early-stage candidates for various cancers, including kidney cancer and glioblastoma, and as the number of product approvals increases, the company will enhance its R&D capabilities and market competitiveness.
- Acquisition Enhances Competitiveness: Telix's $250 million acquisition of RLS Pharmacies established a radiopharmacy network with 31 locations, providing a competitive edge in the rapid delivery of radiopharmaceuticals, which is crucial given their short shelf lives.
See More
Telix Pharmaceuticals to Participate in Two Major Healthcare Conferences
- Conference Participation: Telix Pharmaceuticals will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, showcasing its latest advancements in biopharmaceuticals.
- Executive Presentations: CEO Christian Behrenbruch will engage in a fireside chat at the Oppenheimer conference, expected to share insights on Telix's strategic direction and future plans, thereby boosting investor confidence in the company.
- Live Webcasting: Both sessions will be webcast live through Telix's Investor Relations website, ensuring that global investors can access real-time updates on the company's developments, enhancing transparency and market engagement.
- Global Business Expansion: Telix is actively expanding its operations worldwide, with a presence in the U.S., U.K., Brazil, Canada, Europe, and Japan, focusing on developing therapeutic and diagnostic radiopharmaceuticals to address significant unmet medical needs in oncology and rare diseases.
See More
Telix Hosts Webinar on Innovations in PSMA-PET/CT Imaging for Prostate Cancer
- Webinar Announcement: Telix Pharmaceuticals is set to host a webinar on March 4, 2026, inviting medical experts to discuss innovations in PSMA-PET/CT imaging for prostate cancer, which is expected to attract a wide range of healthcare professionals and enhance the company's influence in the oncology imaging sector.
- Strong Expert Lineup: The speakers include Dr. Rodney Hicks from the University of Melbourne and Dr. Paul Yonover from UroPartners, showcasing Telix's extensive connections and collaborations in the medical community, potentially boosting investor confidence in the company's future developments.
- Global Business Presence: With its headquarters in Melbourne, Australia, Telix has expanded its international operations to the U.S., U.K., Brazil, Canada, Europe, and Japan, indicating its commitment to addressing global market needs in oncology and rare diseases, thereby enhancing its competitive edge.
- Commitment to Innovation: Telix focuses on developing therapeutic and diagnostic radiopharmaceuticals aimed at addressing significant unmet medical needs in oncology, which is expected to drive future growth through continuous technological advancements and enhance shareholder value.
See More
Telix Pharmaceuticals Hosts Webinar on Prostate Imaging Innovations
- Webinar Announcement: Telix Pharmaceuticals is set to host a webinar on March 4, 2026, featuring key opinion leaders discussing innovations in PSMA-PET/CT imaging for prostate cancer, which is expected to attract attention from investors and healthcare professionals, thereby enhancing the company's influence in the medical imaging field.
- Strong Expert Lineup: The speakers include Dr. Rodney Hicks from the University of Melbourne and Dr. Paul Yonover from UroPartners, showcasing Telix's extensive connections and influence in the medical community, potentially boosting investor confidence in the company's future developments.
- Global Business Presence: Telix operates internationally across the U.S., U.K., Brazil, Canada, Europe, and Japan, focusing on the development of radiopharmaceuticals for oncology and rare diseases, highlighting its strategic importance and market potential in the biopharmaceutical sector.
- Strengthening Investor Relations: By hosting this webinar, Telix aims to enhance interaction with investors and demonstrate its innovative capabilities in prostate cancer imaging technology, intending to improve its brand image and attract more investor interest in its future product development and market performance.
See More
Telix Collaborates with University Hospital Essen on Prostate Cancer Research
- Research Collaboration Initiated: Telix Pharmaceuticals has partnered with University Hospital Essen to launch the PROMISE-PET registry study, aimed at evaluating the prognostic value of PSMA-PET imaging through artificial intelligence, thereby standardizing prostate cancer management.
- Data Collection Scale: Since 2018, the registry has collected data from over 15,000 patients and standardized PET readings across more than 50 institutions globally, demonstrating the potential of PSMA-PET as a novel prognostic biomarker for prostate cancer.
- AI Model Development: The new collaboration will leverage Telix's automated machine learning platform to develop survival prediction models based on 68Ga-PSMA-11-PET imaging data, aiming to enhance the accuracy and effectiveness of clinical decision-making.
- Significant Clinical Impact: PSMA-PET imaging is recognized as a significant advancement in prostate cancer management, offering greater accuracy than conventional imaging, and is expected to influence clinical guidelines and decision-making through improved risk stratification.
See More
Telix Pharmaceuticals: Unlocking Potential in Cancer Diagnostics Market
- Market Growth Potential: A study by Precedence Research forecasts that the cancer diagnostics market will grow at a compound annual growth rate of 8.33% from 2026 to 2035, reaching $378.4 billion, highlighting rapid development and investment opportunities in this sector.
- Rapid Revenue Growth: Telix Pharmaceuticals reported revenue of $804 million in 2025, a 56% increase, with projections for 2026 revenue between $950 million and $970 million, primarily driven by sales progress of Illuccix and Gozellix, indicating increasing market acceptance of its products.
- Diversified Product Portfolio: Telix has two key drugs, TLX591 and TLX250, in phase 3 trials targeting prostate and kidney cancers, respectively, while also pursuing approvals for Zircaix and Pixclara, showcasing its extensive positioning in cancer treatment.
- Building Competitive Advantage: By acquiring RLS Pharmacies for $250 million, Telix established a radiopharmacy network with 31 locations, ensuring distribution capabilities for its radiopharmaceuticals, thereby gaining a significant edge in the market and enhancing its competitive position.
See More
Telix Pharmaceuticals Reports 56% Revenue Growth in 2025
- Significant Revenue Growth: Telix Pharmaceuticals reported a revenue of $804 million in 2025, marking a 56% increase, indicating strong market demand for cancer treatments and likely continued investor interest in the company.
- Optimistic Sales Outlook: Management forecasts 2026 revenue between $950 million and $970 million, a 19% increase at the midpoint, primarily driven by sales progress of Illuccix and Gozellix, reflecting growing market acceptance of its products.
- R&D Pipeline Expansion: Telix is advancing four late-stage and six early-stage candidates for various cancers, including kidney cancer and glioblastoma, and as the number of product approvals increases, the company will enhance its R&D capabilities and market competitiveness.
- Acquisition Enhances Competitiveness: Telix's $250 million acquisition of RLS Pharmacies established a radiopharmacy network with 31 locations, providing a competitive edge in the rapid delivery of radiopharmaceuticals, which is crucial given their short shelf lives.
See More
Telix Pharmaceuticals to Participate in Two Major Healthcare Conferences
- Conference Participation: Telix Pharmaceuticals will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, showcasing its latest advancements in biopharmaceuticals.
- Executive Presentations: CEO Christian Behrenbruch will engage in a fireside chat at the Oppenheimer conference, expected to share insights on Telix's strategic direction and future plans, thereby boosting investor confidence in the company.
- Live Webcasting: Both sessions will be webcast live through Telix's Investor Relations website, ensuring that global investors can access real-time updates on the company's developments, enhancing transparency and market engagement.
- Global Business Expansion: Telix is actively expanding its operations worldwide, with a presence in the U.S., U.K., Brazil, Canada, Europe, and Japan, focusing on developing therapeutic and diagnostic radiopharmaceuticals to address significant unmet medical needs in oncology and rare diseases.
See More
